Similar articles for PMID: 26131911

Year	Number of Results
1995	1
1999	1
2002	2
2003	2
2005	2
2006	1
2007	1
2008	1
2009	5
2010	8
2011	11
2012	16
2013	21
2014	25
2015	22
2016	25
2017	32
2018	31
2019	29
2020	29
2021	51
2022	33
2023	12
2024	1

1

Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.

Pinter M, Ulbrich G, Sieghart W, Kölblinger C, Reiberger T, Li S, Ferlitsch A, Müller C, Lammer J, Peck-Radosavljevic M. Pinter M, et al. Radiology. 2015 Dec;277(3):903-12. doi: 10.1148/radiol.2015142140. Epub 2015 Jul 1. Radiology. 2015. PMID: 26131911 Clinical Trial.

2

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB. Kloeckner R, et al. BMC Cancer. 2015 Jun 10;15:465. doi: 10.1186/s12885-015-1480-x. BMC Cancer. 2015. PMID: 26059447 Free PMC article. Clinical Trial.

3

Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.

Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, Hou ZH, Huang P, Zhang S, Li Z, Zhu XL, Ni CF. Zhang L, et al. AJR Am J Roentgenol. 2021 Oct;217(4):933-943. doi: 10.2214/AJR.20.24708. Epub 2020 Nov 27. AJR Am J Roentgenol. 2021. PMID: 33245680

4

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J. Lencioni R, et al. J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22. J Hepatol. 2016. PMID: 26809111 Clinical Trial.

5

Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.

Lee YK, Jung KS, Kim DY, Choi JY, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim GM, Kim MD, Park SI, Won JY, Lee DY. Lee YK, et al. J Gastroenterol Hepatol. 2017 Feb;32(2):487-496. doi: 10.1111/jgh.13501. J Gastroenterol Hepatol. 2017. PMID: 27503585

6

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.

Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Salem R, et al. Gastroenterology. 2016 Dec;151(6):1155-1163.e2. doi: 10.1053/j.gastro.2016.08.029. Epub 2016 Aug 27. Gastroenterology. 2016. PMID: 27575820 Free PMC article. Clinical Trial.

7

Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.

Kang YJ, Lee BC, Kim JK, Yim NY, Kim HO, Cho SB, Jeong YY. Kang YJ, et al. Cardiovasc Intervent Radiol. 2020 Jan;43(1):55-64. doi: 10.1007/s00270-019-02349-9. Epub 2019 Oct 23. Cardiovasc Intervent Radiol. 2020. PMID: 31646378

8

Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.

Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF. Cosgrove DP, et al. Radiology. 2015 Nov;277(2):594-603. doi: 10.1148/radiol.2015142481. Epub 2015 Jun 11. Radiology. 2015. PMID: 26069923 Clinical Trial.

9

Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.

Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C, Peck-Radosavljevic M, Sieghart W. Pinter M, et al. Radiology. 2012 May;263(2):590-9. doi: 10.1148/radiol.12111550. Epub 2012 Mar 21. Radiology. 2012. PMID: 22438359

10

Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival.

Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ. Chung GE, et al. Radiology. 2011 Feb;258(2):627-34. doi: 10.1148/radiol.10101058. Radiology. 2011. PMID: 21273524

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

308 results

Results by year